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Tolerance induction in T cells takes place in most
tumors and is thought to account for tumor evasion
from immune eradication. Production of the cytokine
TGF-b is implicated in immunosuppression, but
the cellular mechanism by which TGF-b induces
T cell dysfunction remains unclear. With a transgenic
model of prostate cancer, we showed that tumor
development was not suppressed by the adaptive
immune system, which was associated with height-
ened TGF-b signaling in T cells from the tumor-drain-
ing lymph nodes. Blockade of TGF-b signaling in
T cells enhanced tumor antigen-specific T cell res-
ponses and inhibited tumor development. Surpris-
ingly, T cell- but not Treg cell-specific ablation of
TGF-b1 was sufficient to augment T cell cytotoxic
activity and blocked tumor growth and metastases.
These findings reveal that T cell production of TGF-
b1 is an essential requirement for tumors to evade
immunosurveillance independent of TGF-bproduced
by tumors.
INTRODUCTION
Cancer develops as a result of intricate interactions between
tumor cells and their environment. How the immune system
responds to tumors is of interest not only for the understanding
of diseasemechanisms but also for cancer immunotherapy (Gat-
tinoni et al., 2006; Pardoll, 2003). Studies in mice and humans
have demonstrated that the host mounts antibody and T cell
responses to tumor-associated antigens (Boon et al., 2006;
Lee et al., 1999; Savage et al., 2008; Schietinger et al., 2008; Wil-
limsky and Blankenstein, 2005). The outcomes of adaptive
immune responses to cancer, however, appear to depend on
tumor types and mechanisms of cell transformation. Experi-
ments utilizing recombination-activating gene (Rag)-deficient
mice have reported increased incidence of carcinogen-induced
tumors (Shankaran et al., 2001). Antibody depletion of CD4+ andCD8+ T cells or neutralization of interferon-g (IFN-g) results in
tumor outgrowth in wild-typemice (Koebel et al., 2007), suggest-
ing that lymphocyte-mediated tumor rejection is dependent on
type 1 T cell responses. In addition, tumors that develop under
the conditions of immune deficiency are more immunogenic
than tumors that develop in wild-type mice (Koebel et al.,
2007; Shankaran et al., 2001). Although tumor antigen-specific
T cell responses have yet to be demonstrated to suppress
carcinogen-induced tumors, these findings provide compelling
evidence that adaptive immunity can inhibit tumor growth and
shape tumor immunogenicity, and thus support the cancer
immunoediting hypothesis (Dunn et al., 2002; Swann and Smyth,
2007).
Tumors are frequently associated with genetic alterations
affecting oncogenes and tumor-suppressor genes. In genetic
models of mouse cancer, the functions of T cells in controlling
of tumor development are incompletely understood. Mice
heterozygous for the tumor suppressor p53 develop accelerated
B cell lymphoma on a genetic background deficient in perforin
(Smyth et al., 2000b), the pore-forming protein crucial for the
cytolytic activity of CD8+ T cells and NK cells. Lymphomas that
develop in these mice are rejected upon transplantation into
wild-type mice but grow progressively in perforin-deficient
mice or wild-type mice depleted of CD8+ T cells (Smyth et al.,
2000b). These observations imply a cytotoxic T lymphocyte-
dependent surveillance mechanism of spontaneous B cell lym-
phomas. T cell-mediated rejection of tumors, however, is not
observed in other strains of cancer-prone mice. In a transgenic
model of spontaneous cancer, expression of the oncogene
simian virus 40 T antigen (SV40 Tag) is triggered by stochastic
events in diverse tissues (Willimsky and Blankenstein, 2005).
Although tumors induce Tag-specific B cell and T cell responses,
Tag-specific CD8+ T cells are unable to kill target cells (Willimsky
and Blankenstein, 2005; Willimsky et al., 2008). These findings
reveal that sporadic tumors do not escape immune recognition,
but induce T cell tolerance. We have recently identified a histone
H4 peptide as a tumor-associated antigen for CD8+ T cells in
transgenic adenocarcinoma of mouse prostate (TRAMP) mice
(Savage et al., 2008). Adoptive transfer of H4 antigen-reactive
T cell-receptor transgenic (HRC) T cells into TRAMP shows
that HRC T cells lack effector function (Savage et al., 2008).
These observations suggest that defective effector T cellImmunity 35, 123–134, July 22, 2011 ª2011 Elsevier Inc. 123
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Figure 1. Absence of Adaptive Immunity Does Not Increase the Susceptibility of TRAMP Mice to Tumor Development
(A and B) Flow cytometric analysis of lymphocytes infiltrating the prostates of 8-month-old TRAMP mice. The percentage of B220- and TCR-b-expressing cells
among CD45+ cells (A) and the percentage of CD4+ and CD8+ T cells in TCR-b-positive cells (B) are shown.
(C) Littermates of wild-type TRAMP and Rag1/ TRAMP mice were evaluated for tumor development at 8 months of age. The weights (Wt) of urogenital tracts
(UG) normalized to bodyWt ± SEMof wild-type TRAMP (n = 17) andRag1/-TRAMP (n = 16)mice are shown. The p value between two groups of tumor burden is
shown (Wilcoxon rank-sum test).
Immunity
Tolerance in TRAMP Tumors Requires T Cell TGF-b1differentiation is probably a general phenomenon in models of
oncogene-induced cancer.
The precise mechanisms of T cell tolerance to autochthonous
tumors remain unknown. Many variables probably contribute to
the T cell hyporesponsive phenotype in tumor-bearing mice
(Blankenstein, 2007; Drake et al., 2006; Rabinovich et al.,
2007). Transforming growth factor-b (TGF-b) is a regulatory cyto-
kine with a well-documented role in inhibiting autoreactive T cell
responses (Li and Flavell, 2008; Li et al., 2006; Marie et al., 2006;
Ouyang et al., 2010). TGF-b elicits its biological activity by
binding the serine or threonine kinases TGF-b type I (TGF-bRI)
and type II (TGF-bRII) receptors leading to the phosphorylation
and activation of Smad2 and Smad3 transcription factors
(Li and Flavell, 2008). In studies of transplantable tumor cell lines,
inhibition of TGF-b signaling in T cells through the expression of
a dominant-negative mutant of TGF-bRII or the administration of
blocking antibodies or soluble TGF-bRII results in enhancement
of T cell responses and the inhibition of tumor growth (Gorelik
and Flavell, 2001; Liu et al., 2007; Nam et al., 2008; Thomas
and Massague´, 2005; Zhang et al., 2005). However, important
caveats are associated with transplanted tumor models such
as potential microbe contamination of tumor cell lines and induc-
tion of tissue damage upon tumor cell inoculation, which may
serve as adjuvants to stimulate T cell responses. Whether
TGF-b signaling in T cells naturally suppresses tumor-reactive
T cell responses to autochthonous tumors has not been
investigated.
There are three family members of TGF-b in mammals, among
which TGF-b1 is the most widely distributed cytokine expressed
by tumor cells, as well as various subsets of leukocytes and
stromal cells (Bierie and Moses, 2010; Flavell et al., 2010;
Massague´, 2008). An early study showed that overexpression
of an active form of TGF-b1 in a highly immunogenic tumor cell
line suppresses the antitumor immune responses (Torre-Amione
et al., 1990), which led to the generally accepted assumption that
tumor cell-produced TGF-b inhibits T cell responses and
promotes tumor immune evasion. However, RNA interference-
mediated knockdown of tumor-derived TGF-b1 does not
enhance antitumor T cell responses in a transplantation model,
whereas tumor expression of a soluble formof TGF-bRII, a decoy
receptor for TGF-b produced by tumors and cells in the vicinity of
tumors, enhances T cell cytolytic activity (Thomas and Mas-124 Immunity 35, 123–134, July 22, 2011 ª2011 Elsevier Inc.sague´, 2005). These findings suggest that TGF-b1 produced
by host cells may play a more important role in inhibiting T cell
responses to tumors. The precise in vivo source(s) of TGF-b1
mediating T cell tolerance to tumors remains to be determined.
In this report, we have utilized a transgenic mouse model of
prostate cancer to investigate the role of TGF-b1 in control of
T cell responses to spontaneous tumors. We found that the
adaptive immune system did not naturally protect mice from
tumor development, which was associated with enhanced
TGF-b signaling in T cells from the tumor-draining lymph nodes.
T cell-specific blockade of TGF-b signaling augmented tumor
antigen-specific T cell proliferation and effector T cell differenti-
ation and inhibited tumor progression to advanced stages. In
addition, T cells were found to be the major producers of
TGF-b1 that conferred the enhanced TGF-b signaling in tumor-
draining lymph node T cells. Consequently, T cell-specific dele-
tion of the Tgfb1 gene inhibited tumor growth and metastatic
dissemination. These results reveal that the T cell-intrinsic
TGF-b signaling pathway inhibits T cell surveillance of autoch-
thonous prostate tumors.
RESULTS
Adaptive Immunity Does Not Suppress Tumor
Development in TRAMP Mice
To assess immune response to autochthonous tumors, we used
a model in which transgenic adenocarcinoma of mouse prostate
(TRAMP) mice express the well-characterized onocogene SV40
Tag under the control of a prostate-specific promoter (Greenberg
et al., 1995).Weanalyzedbyflowcytometry the immunecells infil-
trating the prostate tumors of 8-month-old TRAMPmice. Among
the CD45-positive cells found in the prostates, 57.7% ± 4.4%
expressed the T cell marker TCR-b, whereas 7.5% ± 2.7% ex-
pressed the B cell marker B220 (Figure 1A). In the T cell compart-
ment, 55.0%± 6.2% of the infiltrates were CD8+ T cells, whereas
15.9%± 3.1%were CD4 positive (Figure 1B). Thus, T cells domi-
nate the adaptive immune cell infiltrates in TRAMP mice.
A previous study demonstrated that deletion of NKG2D,
a stimulatory receptor that is expressed by natural killer cells
and activated T cells, results in increased incidence of large
highly malignant early prostate carcinomas in TRAMP mice
(Guerra et al., 2008), suggesting a critical role for NKG2D in
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Figure 2. Enhanced TGF-b Signaling in T Cells from Tumor-Draining Lymph Nodes of TRAMP Mice
(A) Flow cytometric analysis of Smad2 and Smad3 phosphorylation in CD4+ and CD8+ T cells from 8-month-old wild-type prostate tumor-bearing TRAMP mice.
Draining LNs represents lymph nodes draining prostate, Ctrl LNs represents control axillary and brachial lymph nodes, and Isotype Ctrl represents isotype control
antibody staining.
(B and C) Smad2 and Smad3 phophorylation in CD4+ and CD8+ T cells from prostate tumor-draining lymph nodes (B) and prostates (C) of TRAMP and
DNR-TRAMP mice as determined by flow cytometry.
Representatives of five independent experiments are shown.
Immunity
Tolerance in TRAMP Tumors Requires T Cell TGF-b1tumor surveillance. However, because the aforementioned
study employed total NKG2D deletion, it was not possible to
distinguish the role of NKG2D in innate versus adaptive immune
cells. To determine the importance of adaptive immunity in inhib-
iting tumor growth, we crossed TRAMPmice to mice deficient in
the Rag1 gene to obtain Rag1/-TRAMP mice. Surprisingly,
absence of the adaptive immune system did not affect tumor
development in TRAMPmice in comparison to wild-type TRAMP
mice (Figure 1C). These results suggest that in spite of profound
T cell infiltration into the prostate tumors of TRAMP mice, T cells
cannot control tumor development.
Tumor Growth Triggers Enhanced TGF-b Signaling in
Tumor-Draining Lymph Node T Cells
We wished to investigate the mechanisms underlying the T cell
defects in TRAMP mice. Recent studies have demonstrated
that T cell tolerance in tumor-bearing mice is associated with
increased production of TGF-b1 (Willimsky and Blankenstein,
2005; Willimsky et al., 2008). To determine whether TGF-b
signaling in T cells is modulated during TRAMP tumor develop-
ment, we evaluated Smad protein phosphorylation in 8-month-
old TRAMP mice by flow cytometry. Smad2 and Smad3
phosphorylation was elevated in CD4+ and CD8+ T cells from
tumor-draining periaortic lymph nodes compared to CD4+ and
CD8+ T cells from other tissues (Figure 2A). Analysis of age-
matched C57BL/6 mice revealed comparable Smad phospho-rylation in T cells from periaortic lymph nodes and the other
peripheral lymphoidorgans (data not shown). Thus, tumorgrowth
in TRAMP mice specifically triggers the enhanced Smad2 and
Smad3 activation in tumor-draining lymph node T cells.
To investigate whether the elevated Smad2 and Smad3 phos-
phorylation was due to TGF-b or other Smad activators such as
activin proteins, we crossed TRAMP mice with a transgenic
mouse line in which T cell TGF-b signaling was attenuated by
the expression of a dominant-negative form of TGF-bRII (DNR)
(Gorelik and Flavell, 2000). Indeed, Smad2 and Smad3 phos-
phorylation in T cells from the tumor-draining lymph nodes of
DNR-TRAMP mice was diminished compared to that of wild-
type TRAMPmice (Figure 2B), whereas Smad protein phosphor-
ylation in tumor-infiltrated T cells was comparable (Figure 2C).
Thus, TGF-b signaling in T cells is regulated during oncogene-
induced primary tumor development. Notably, these results indi-
cate that the heightened T cell TGF-b signaling coincides with
T cell priming in the tumor-draining lymph nodes.
Blockade of T Cell TGF-b Signaling Inhibits Tumor
Development in TRAMP Mice
TRAMPmice develop prostate tumors after the onset of puberty
and the tumors grow progressively and eventually kill the mice at
8–10months of age (Greenberg et al., 1995). Furthermore, tumor
growth in TRAMP mice profoundly induces tolerance in T cells
(Anderson et al., 2007; Bai et al., 2008; Savage et al., 2008). ToImmunity 35, 123–134, July 22, 2011 ª2011 Elsevier Inc. 125
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Figure 3. Blockade of TGF-b Signaling in
T Cells Protects TRAMP Mice from Tumor
Development
(A) The weights (Wt) of urogenital tracts (UG)
normalized to bodyWt ± SEM of wild-type TRAMP
(n = 18) andDNR-TRAMP (n = 19)mice at 8months
of age. The p value between two groups of
tumor burden is shown (Wilcoxon rank-sum test).
Asterisk depicts statistically significant difference.
(B) Histological analysis of sections of the pros-
tates of 8-month-old TRAMP and DNR-TRAMP
mice. Sections of representative prostates from
TRAMP and DNR-TRAMP mice were stained with
hematoxylin and eosin. Black arrows indicate
neoplastic polyps. Yellow arrows indicate clusters
of mononuclear cells.
(C) Pathologic scoring for stages of tumor devel-
opment in the prostates of littermates of TRAMP
and DNR-TRAMP mice. 1, normal; 2, low-grade
intraepithelial neoplasia; 3, high-grade intra-
epithelial neoplasia; 4, well-differentiated prostate
adenocarcinoma; 5, moderately differentiated
prostate adenocarcinoma; 6, poorly differentiated
prostate adenocarcinoma.
Immunity
Tolerance in TRAMP Tumors Requires T Cell TGF-b1investigate the direct effect of TGF-b signaling in T cells on tumor
immunosurveillance, we first examined tumor development in
DNR-TRAMP mice. In contrast to wild-type TRAMP mice that
had high tumor burden at 8 months of age, prostate tumor
growth was inhibited in DNR-TRAMP mice (Figure 3A). Histo-
pathologically, wild-type TRAMPmice had large prostatic glands
that contained neoplastic polyps, but these polyps were absent
in the prostates of DNR-TRAMP mice (Figure 3B). Instead, clus-
ters of mononuclear cells heavily infiltrated the prostates of
DNR-TRAMP mice (Figure 3B). When prostate tumors did
appear in DNR-TRAMPmice, theywere prevented from reaching
advanced stages (histopathologic score 5 or 6) in comparison to
wild-type TRAMP mice in which approximately 40% of prostate
tumors evaluated had a score of 5 or higher (Figure 3C).
To determine the underlyingmechanism of tumor protection in
DNR-TRAMPmice, we first examined the numbers of T cells infil-
trating the prostates. We found 3-fold more CD4+ and CD8+
T cells in the prostates of DNR-TRAMP mice than those in
wild-type TRAMP mice (Figures 4A and 4B). By immunohisto-
chemical staining, increased CD3 staining was observed in the
prostates of DNR-TRAMP mice, and these CD3-positive T cells
localized to both the glands and stroma, whereas weak CD3
reactivity was mostly found in the tumor stroma of wild-type
mice (see Figure S1 available online). Altogether, these observa-
tions demonstrate that TGF-b signaling in T cells inhibits T cell
expansion and/or tumor infiltration, which prevents T cell tumor
surveillance in TRAMP mice.
Recent studies showed that the killer cell cytotoxic pathway
molecule perforin and the cytokine IFN-g are required for the
immunosurveillance of spontaneous malignancies as well as
methylcholanthrene-induced sarcomas (Koebel et al., 2007;
Shankaran et al., 2001; Smyth et al., 2000b; Street et al., 2002;
vandenBroeket al., 1995). Furthermore, rejectionof transplanted
tumors inmicewith T cell-specific inactivation of TGF-b signaling
requires CTLs with enhanced expression of IFN-g and GzmB
(Gorelik and Flavell, 2001; Thomas and Massague´, 2005). In line
with these observations, CD8+ T cells from tumor-draining lymph126 Immunity 35, 123–134, July 22, 2011 ª2011 Elsevier Inc.nodes of DNR-TRAMP mice expressed high amounts of IFN-g
and GzmB (Figure 4C). Enhanced IFN-g was also detected in
CD4+ T cells from the draining lymph nodes of DNR-TRAMP
mice (Figure 4C and data not shown). The expression of GzmB,
but not IFN-g, was further increased in tumor-infiltrated CD8+
T cells from DNR-TRAMP mice (Figure 4C). Thus, blockade of
TGF-b signaling in T cells results in T cell differentiation into effec-
tors with augmented protective antitumor immunity.
Programmed death 1 (PD-1) is an inhibitory coreceptor that is
expressedby activated T cells (Keir et al., 2008). PD-1 expression
limits effector T cell responses and is critical for the induction and
maintenance of T cell dysfunction in tumors (Fourcade et al.,
2010; Keir et al., 2008). Analysis of wild-type TRAMP mice
showed that CD8+ T cells expressed high amounts of PD-1 in
the prostate but not in the tumor-draining lymph nodes (Fig-
ure 4C). Blockade of TGF-b signaling in T cells led to diminished
PD-1 expression in tumor-infiltrating CD8+ T cells (Figure 4C). In
addition to inhibitory coreceptors, immune suppression by CD4+
Foxp3+ regulatory T (Treg) cells hasbeen implicated in restraining
antitumor immune responses (Curiel et al., 2004; Turk et al., 2004;
Yamaguchi and Sakaguchi, 2006). Our previous studies have re-
vealed a dual function for TGF-b signaling in inhibiting Treg cell
proliferation and in enhancing Treg cell survival (Li et al., 2006;
Ouyang et al., 2010). Attenuated TGF-b signaling in T cells in
TRAMPmice resulted inTregcell expansion in the tumor-draining
lymph nodes (Figure S2), whereas Treg cell frequencies
decreased in the prostates (Figure S2). Thus, antitumor immunity
in DNR-TRAMP mice is associated with reduced T cell intrinsic
and extrinsic inhibitory signals at the tumor site.
TGF-b Suppression of Antitumor Immune Responses
Is Tumor Antigen Specific
One caveat with spontaneous protective antitumor T cell
responses as reported here is that it could be a result of
secondary effects of generally enhanced inflammation in DNR
mice (Gorelik and Flavell, 2000), although we kept DNR-TRAMP
mice on a diet with antibiotics that prevented the prominent
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Figure 4. TGF-b Signaling Regulates T Cell Responses to Tumors
(A and B) Cell counts of T lymphocytes isolated from the prostates of 8-month-old mice. Results shown are the absolute numbers normalized to weights (Wt) of
urogenital tracts (UG) ± SEMof CD4+ (A) and CD8+ (B) T cells infiltrating the prostates of TRAMP (n = 20) and DNR-TRAMP (n = 20)mice. The p values between the
two groups of T cell numbers are shown (Wilcoxon rank-sum test). Asterisk depicts statistically significant difference.
(C) Flow cytometric analysis examining the expression of interferon gamma (IFN-g), granzyme B (GzmB), and PD-1 proteins in CD4+ and CD8+ T cells in the
draining lymph nodes and prostates of TRAMP and DNR-TRAMPmice. For IFN-g expression, T cells were restimulated in vitro for 5 hr with phorbol 12-myristate
13-acetate (PMA), ionomycin, and GolgiStop.
Representatives of five independent experiments are shown. See also Figures S1 and S2.
Immunity
Tolerance in TRAMP Tumors Requires T Cell TGF-b1colitis phenotype that develops in these mice. Therefore, in the
absence of defined tumor-associated antigens to track tumor-
specific responses, interpretations of results could be compli-
cated. In an earlier study, we identified a naturally arising CD8+
T cell receptor (TCR) that is reactive to a histone H4 peptide
uniquely recognized during tumor development in TRAMP
mice (Savage et al., 2008). We have generated a strain of H4
peptide-reactive TCR transgenic (HRC) mice. In adoptive trans-
fer experiments, HRC T cells are able to recognize the endoge-
nous tumor-associated antigen but are bereft of effector activity
(Savage et al., 2008). Therefore, HRC T cells represent an ideal
tool to analyze the molecular basis of tumor antigen-specific
T cell tolerance. To this end, we crossed DNR mice with HRC
mice onto a Rag1-deficient background and purified naive
wild-type HRC and DNR-HRC T cells and adoptively transferred
these cells into tumor-bearing wild-type TRAMP mice (Fig-
ure 5A). Based on CFSE dilution, proliferation of wild-type HRC
and DNR-HRC cells could be detected. Compared to wild-type
HRC T cells, approximately twice as many DNR-HRC T cells
proliferated in the tumor-draining lymph nodes (Figure 5B), sup-
porting a critical role for TGF-b signaling in inhibiting tumor
antigen-specific T cell priming.We also detected that three timesmore activated (CFSE-low) DNR-HRC T cells infiltrated prostate
tumors (Figure 5B), among which a higher proportion acquired
effector function as determined by GzmB production than
wild-type HRC T cells (Figure 5B). These observations demon-
strate that TGF-b signaling regulates tumor antigen-specific
T cell proliferation and effector T cell differentiation.
T Cell-Produced TGF-b1 Controls Tumor Development
in TRAMP Mice
Studies using cell lines and tumor transplantation have sug-
gested that immunosuppression is attributable to tumor-
produced TGF-b (Friese et al., 2004; Kao et al., 2003; Liu et al.,
2007; Torre-Amione et al., 1990). Nevertheless, shRNA knock-
down of TGF-b1 in EL-4 cells revealed that the absence of
tumor-derived TGF-b1 was not sufficient to confer protection
against tumors (Thomas and Massague´, 2005), which could be
explained by redundant functions of TGF-b2 and TGF-b3. An
alternative explanation is that TGF-b1 derived from host cells
plays a more crucial role in T cell tolerance to tumors. We
showed previously that TGF-b1 produced by T cells controls
T cell differentiation and tolerance in autoimmunity settings (Li
et al., 2007). To determine whether TGF-b1 production byImmunity 35, 123–134, July 22, 2011 ª2011 Elsevier Inc. 127
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Figure 5. TGF-b Signaling Inhibits Tumor Antigen-Specific T Cell
Proliferation and Effector T Cell Differentiation
Tumor antigen-specific T cell response assessment in TRAMP mice.
(A) Schematic of T cell transfer into tumor-bearing TRAMP mice.
(B) Donor T cell proliferation and GzmB expression as determined by flow
cytometry. A representative of three independent experiments is shown.
Immunity
Tolerance in TRAMP Tumors Requires T Cell TGF-b1T cells might represent a previously unrecognized cellular mech-
anism of T cell tolerance to tumors, we first investigated whether
T cells in tumor-bearing TRAMP mice secreted TGF-b1. By
ELISA, CD4+ and CD8+ T cells from tumor-draining periaortic
lymph nodes produced approximately 50% more TGF-b1 than
T cells from nondraining lymph nodes (Figure 6A).
To determine the function of T cell-produced TGF-b1 in control
of tumor development, we used mice with floxed/null alleles
(Tgfb1f/n) of TGF-b1 crossed with Cd4cre transgenic mice (Li
et al., 2007). Tgfb1f/n Cd4cre mouse line was further crossed to
TRAMP mice to obtain Tgfb1f/n Cd4cre-TRAMP mice. T cells in
the tumor-draining lymph nodes of Tgfb1f/n Cd4cre-TRAMP
mice had attenuated Smad2 and Smad3 phosphorylation (Fig-
ure 6B), indicating that T cell-produced TGF-b1 accounted in
part for the enhanced TGF-b signaling in T cells. To assess for
specific causality between T cell-produced TGF-b1 and host
susceptibility to tumors, we monitored Tgfb1f/n Cd4cre-TRAMP
mice for tumor development. Similar to DNR-TRAMP mice,
tumor development was inhibited in Tgfb1f/n Cd4cre-TRAMP
mice (Figure 6C). In the absence of T cell-derived TGF-b1,
CD4+ and CD8+ T cells in TRAMP tumors acquired effector func-
tions such as increased expression of IFN-g in the draining
lymph nodes and GzmB expression in CD8+ T cells upon tumor
infiltration (Figure 6D). In addition, CD8+ T cells infiltrating the
prostates of Tgfb1f/n Cd4cre-TRAMP mice had diminished PD-
1 expression (Figure 6C). Analogous to DNR-TRAMP mice,
Treg cell frequencies increased in the tumor-draining lymph no-
des but not in the prostates of Tgfb1f/n Cd4cre-TRAMP mice
(Figure S3). These results indicate that a deficit in T cell128 Immunity 35, 123–134, July 22, 2011 ª2011 Elsevier Inc.TGF-b1 production is sufficient to break T cell tolerance to spon-
taneous prostate tumors.
Treg Cell-Produced TGF-b1 Is Dispensable for the
Induction of Tumor Immune Tolerance
Studies have shown that increased numbers of Treg cells predict
unfavorable clinical outcomes (Curiel et al., 2004; Turk et al.,
2004; Yamaguchi and Sakaguchi, 2006). Recently, we showed
in a transfer model of colitis that Treg cell-produced TGF-b1
inhibits Th1 cell differentiation (Li et al., 2007), but it is dispens-
able for Th17 cell differentiation in a model of experimental auto-
immune encephalomyelitis (Gutcher et al., 2011). To determine
the function of Treg cell-produced TGF-b1 in tumor immune
tolerance, we generated a Treg cell-specific TGF-b1-deficient
mouse strain by crossing Tgfb1f/n mice with Foxp3cre mice
(Gutcher et al., 2011). Tgfb1f/n Foxp3cre mice were further
crossed with TRAMP mice to obtain Tgfb1f/n Foxp3cre-TRAMP
mice. We found that, concomitant with the lack of protection
from tumor development, T cells from Tgfb1f/n Foxp3cre-TRAMP
mice failed to differentiate into effectors (Figures S4A and S4B).
Consistent with our recent finding that Treg cell-produced
TGF-b1 inhibits Treg cell expansion (Gutcher et al., 2011), the
numbers of Treg cells increased in the tumor-draining lymph no-
des but not in the prostates of Tgfb1f/n Foxp3cre-TRAMP mice
(Figure S4C). Therefore, Treg cell-produced TGF-b1 is not
essential for the induction of T cell tolerance in TRAMP mice.
T Cell-Produced TGF-b1 Promotes Tumor Metastatic
Growth
The major cause of mortality in cancer patients is metastastic
dissemination. Given this evidence of a causal relationship
between T cell TGF-b1 production and host failure to survey
for malignancy, we asked whether T cell-produced TGF-b1
would also promote tumor metastasis. Because Tgfb1f/n
Cd4cre-TRAMP mice were protected from prostate tumor
growth, it was not possible to select mice with comparable
primary tumor burdens to assess tumor metastasis. To circum-
vent this limitation and to test the broader applicability of our
observations, we employed an experimental metastasis assay.
We intravenously injected ovalbumin-expressing metastatic
B16 melanoma cells (B16-OVA) into syngeneic Tgfb1f/n and
Tgfb1f/nCd4cremice. Whereas a large number of B16-OVA cells
colonized the lungs in Tgfb1f/n mice, pulmonary metastasis was
greatly diminished in the absence of T cell-produced TGF-b1
(Figures S5A and S5B). Reduced lung colonization was associ-
ated with increased numbers of ovalbumin-specific CD8+
T cells in Tgfb1f/n Cd4cre mice (Figure S5C) that produced
high amounts of GzmB (Figure S5D). Collectively, these results
corroborate our findings with the primary tumors that T cell-
produced TGF-b1 inhibits the expansion and effector differenti-
ation of tumor antigen-specific T cells and further demonstrate
that T cell-produced TGF-b1 promotes tumor metastasis.
To investigate the effects of T cell-produced TGF-b1 on tumor
immune tolerance, Tgfb1f/n and Tgfb1f/n Cd4cre mice were also
challenged intraperitoneally with EL-4, a murine tumor cell line
that secretes large amounts of TGF-b1 (Gorelik and Flavell,
2001). In accordance with the TRAMP and B16-OVA tumor
data, deficiency of TGF-b1 in T cells also prevented EL-4 tumor
establishment in the peritoneal cavity (data not shown), again
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Figure 6. T Cell-Specific Ablation of TGF-b1 Enhances Antitumor T Cell Responses and Inhibits Tumor Development
(A) TGF-b1 production by purified CD4+ and CD8+ T cells from the tumor-draining periaortic lymph nodes and control axillary and brachial lymph nodes of
8-month-old TRAMPmice. Data shown are mean ± SEM (n = 3 per group). The p value between two groups of TGF-b1 concentrations is shown (Student’s t test).
Asterisk depicts statistically significant difference.
(B) Representative flow cytometric analysis of Smad2 and Smad3 phosphorylation in T cells from lymph nodes draining prostates of 8-month-old Tgfb1f/n TRAMP
and Tgfb1f/n Cd4cre (TKO)-TRAMP mice. A representative of three independent experiments is shown.
(C) Evaluation of the weights (Wt) of urogenital tracts (UG) normalized to body Wt ± SEM of Tgfb1f/n TRAMP (n = 9) and TKO-TRAMP (n = 11) mice at 8 months
of age. The p value between the two groups of tumor burden is shown (Wilcoxon rank-sum test). Asterisk depicts statistically significant difference.
(D) Expression of IFN-g, GzmB, and PD-1 in CD4+ and CD8+ T cells in Tgfb1f/n TRAMP and TKO-TRAMP mice.
Data are representative of three independent experiments. See also Figures S3 and S4.
Immunity
Tolerance in TRAMP Tumors Requires T Cell TGF-b1supporting an essential role for T cell-derived TGF-b1 in fostering
malignancy. Next we examined tumor-specific cytolytic activity
with splenocytes to kill EL-4 target cells. Splenocytes from
Tgfb1f/n Cd4cre mice showed significantly higher EL-4-specific
cytolytic activity than splenocytes from Tgfb1f/n mice (Figure 7A).
It has recently been demonstrated that rejection of transplanted
tumors under conditions of abrogated T cell TGF-b signaling is
mediated by the cytolytic activity of CD8+ T cells although it
requires the provision of CD4+ T cell help (Gorelik and Flavell,
2001). In other experimental systems, CD4+ T cells acquire suffi-
cient cytotoxic activity to suppress tumor growth (Quezada et al.,
2010; Xie et al., 2010). In line with the increased GzmB expres-
sion in CD8+ T cells from Tgfb1f/n Cd4cre mice, the cytolytic
activity was specifically abrogated when we depleted CD8+
T cells prior to the addition of splenocytes to the target cells
(Figure 7B). These findings imply that tumor protection in
Tgfb1f/n Cd4cre mice is mediated by enhanced tumor-specific
CTL responses.DISCUSSION
The adaptive immune system has evolved to mount robust
responses to pathogens and plays a critical role in inhibiting
virus-induced tumors (Klein and Klein, 1977). However, the
functions of lymphocytes in control of nonviral tumors remain
incompletely understood. In this report, we used an onco-
gene-induced prostate tumor model to show that despite
substantial lymphocyte infiltration into tumors, the adaptive
immune system did not protect mice from tumor development.
This failure of tumor immune protection was mediated by
TGF-b suppression of tumor antigen-specific T cell responses.
TGF-b inhibited T cell priming in the tumor-draining lymph
nodes and impeded T cell proliferation and effector T cell
differentiation. Furthermore, we showed that T cells them-
selves provide the essential source of TGF-b1 for the blockade
of T cell responses to tumors to promote tumor growth and
metastatic dissemination. These findings unveil a crucialImmunity 35, 123–134, July 22, 2011 ª2011 Elsevier Inc. 129
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Figure 7. Enhanced Tumor-Specific Cyto-
lytic CD8+ T Cell Activity in the Absence of
T Cell-Produced TGF-b1
Tgfb1f/n or Tgfb1f/n Cd4cre (TKO) mice were
challenged intraperitoneally with 1 3 106 EL-4
tumor cells.
(A) Cr-51 release assay 10 days after tumor chal-
lenge. Splenocytes were used as effectors against
EL-4 targets. The p values between groups of
Cr-51 release at a given effector:target ratio are
shown (Wilcoxon rank-sum test). Asterisk denotes
statistically significant difference.
(B) Total, CD4+-depleted, or CD8+-depleted
splenocytes from TKO mice were used as
effectors against EL-4 targets at the indicated
effector:target ratios.
See also Figure S5.
Immunity
Tolerance in TRAMP Tumors Requires T Cell TGF-b1immunosuppressive mechanism for tumor-associated T cell
tolerance.
An important finding of this study is that the adaptive immune
system did not naturally inhibit prostate tumor development in
TRAMP mice. These observations, together with findings in
a sporadic tumor model (Willimsky and Blankenstein, 2005;
Willimsky et al., 2008), suggest that oncogene-induced sponta-
neous tumors do not induce protective adaptive immune
responses. Yet, previous studies have provided strong evidence
for T cell-dependent surveillance of carcinogen-induced tumors
(Boesen et al., 2000; Girardi et al., 2001; Koebel et al., 2007;
Shankaran et al., 2001; Smyth et al., 2000a; Svane et al.,
1996). How tumors trigger differential T cell responses in these
models remains to be determined. It is conceivable that exten-
sive mutagenesis is induced during chemical carcinogenesis,
which may generate high-affinity tumor-rejection antigens for
T cells. In an SV40 Tag-induced tumor model, the immunoge-
nicity of transformed cells causes systemic T cell unresponsive-
ness in tumor-bearing mice (Willimsky et al., 2008). Therefore, it
is plausible that tolerance to SV40 Tag-induced tumors may be
associated with the transforming oncogene that itself is a potent
T cell antigen. Future studies of tumors induced by nonantigenic
oncogenes can be used to test this hypothesis. In contrast to
TRAMP mice on Rag1-deficient background, deficiency of the
activating receptor NKG2D leads to enhanced tumor develop-
ment in TRAMP mice (Guerra et al., 2008). NKG2D is expressed
on effector T cells as well as on NK cells. Indeed, in addition to
lymphocytes, high numbers of NK cells infiltrated the tumors in
TRAMP mice (our unpublished observations). These observa-
tions suggest that NK cells may be responsible for NKG2D-
dependent immunosurveillance in these mice. Thus, the effector
functions of lymphocytes and innate immune cells are probably
differentially regulated in response to spontaneous tumor
development.
Multiple mechanisms have been proposed to explain the
induction of T cell tolerance to tumors, such as the lack of
high-affinity T cell antigens, weak costimulation and inflamma-
tion associated with tumor antigen presentation, and the immu-
nosuppressive environment inside tumors (Blankenstein, 2007;
Drake et al., 2006; Rabinovich et al., 2007). With Smad2 and
Smad3 phosphorylation as a readout, we found that tumor
development triggers increased TGF-b signaling in T cells from130 Immunity 35, 123–134, July 22, 2011 ª2011 Elsevier Inc.the tumor-draining lymph nodes, but not in the tumor-infiltrated
T cells. Blockade of TGF-b signaling in T cells resulted in
enhanced T cell proliferation and effector T cell differentiation
in the tumor-draining lymph nodes. Intriguingly, the expression
of the cytolytic enzyme GzmB in CD8+ T cells was further
elevated in the tumor-infiltrated T cells. Although GzmB has
been shown to be a direct target gene of Smad proteins (Thomas
and Massague´, 2005), we cannot exclude the possibility that
there are Smad-independent pathways by which TGF-b
suppresses GzmB expression upon T cell tumor infiltration. An
alternative explanation is that T cell activation and differentiation
in the tumor-draining lymph node has a long-lasting effect on
GzmB expression in tumor-infiltrated T cells. Altogether, these
observations imply a TGF-b-dependent suppressivemechanism
that inhibits antitumor T cell responses at the stage of T cell
priming. In contrast to enhanced GzmB expression, expression
of the inhibitory coreceptor PD-1 in tumor-infiltrating CD8+
T cells was diminished in mice with inhibited TGF-b signaling.
TGF-b might directly promote PD-1 expression in tumor-infil-
trating T cells. In addition, because PD-1 is expressed in ex-
hausted T cells after chronic antigen stimulation, reduced PD-1
expression might be secondary to the tumor protection pheno-
type observed in these mice. The exact mechanism by which
TGF-b regulates PD-1 expression is open for future investigation.
Tumors and other host cells secrete TGF-b, and it has been
unclear which specific cell type-produced TGF-b mediates the
suppression of T cell responses to tumors. Earlier, our work
demonstrated an essential role for T cell-produced TGF-b1 in
the control of Th1 and Th17 cell differentiation and the inflamma-
tory diseases inflicted by the effector CD4+ T cells (Li et al., 2007).
Here in this report, we found that T cell-produced TGF-b1 is also
crucial for the inhibition of CD8+ T cell differentiation to cytolytic
T cells and for the control of tumor development. The absence of
TGF-b1 in T cells resulted in diminished T cell TGF-b signaling in
the tumor-draining lymph node, providing a cellular mechanism
for TGF-b suppression of T cell priming. Tumor growth probably
releases high amounts of tumor-associated antigens. Thus, it is
conceivable that increased T cell TGF-b1 secretion is triggered
by chronic antigen stimulation of T cells in the tumor-draining
lymph nodes. It is important to note that TGF-b1 is secreted as
an inactive form that needs to be liberated from the constraints
of the latency-associated protein (Annes et al., 2003). Recent
Immunity
Tolerance in TRAMP Tumors Requires T Cell TGF-b1studies have revealed that dendritic cell-expressed avb8 integrin
is required for the activation of latent TGF-b1 and for the regula-
tion of T cell responses (Lacy-Hulbert et al., 2007; Travis et al.,
2007). Therefore, the selectively enhanced TGF-b signaling in
tumor-draining lymph node T cells may also be due to the
specific requirement of dendritic cells to prime naive T cells.
However, the exact TGF-b1-producing T cell subset required
for the control of tumor immune tolerance remains to be deter-
mined. Abrogation of TGF-b1 from CD4+Foxp3+ regulatory
T cells was insufficient to inhibit tumor growth, suggesting that
autocrine TGF-b1 might be involved in inhibiting effector T cell
responses to tumors. It is also possible that Treg cell- and
effector T cell-produced TGF-b1 might be redundant in
promoting tumor T cell tolerance. Future studies with T cell
subset-specific TGF-b1-deficient mouse models can be used
to differentiate these possibilities.
Blockade of TGF-b signaling in T cells or T cell-specific dele-
tion of Tgfb1 gene inhibits tumor development in TRAMP mice.
These findings provide strong evidence that in the absence
of self-directed TGF-b signaling in T cells, a spontaneous non-
virus-induced tumor can induce and sustain tumor antigen-
specific T cell responses to protect the host from tumor develop-
ment. Increased TGF-b1 has been detected in another sporadic
tumor model (Willimsky and Blankenstein, 2005; Willimsky et al.,
2008). Importantly, high TGF-b1 levels are specifically associ-
ated with the induction of general cytotoxic T lymphocyte
unresponsiveness in tumor-bearing mice (Willimsky et al.,
2008). Although the precise function of increased TGF-b1
remains to be determined in that model, these observations
suggest that TGF-b-dependent T cell suppression may provide
a general mechanism for defective tumor immunity in mice.
Tumor-specific T cell responses have also been detected in
cancer patients (Boon et al., 2006; Lee et al., 1999); yet, similar
to experimentalmodels, tumors growprogressively as a possible
consequence of failed T cell surveillance. It will therefore be of
great interest to determine whether the self-directed TGF-b
pathway also controls T cell tolerance to primary tumors in
humans.
Disseminatedmetastases are the primary cause of mortality in
cancer patients. Cancer has very complex manifestations;
tumor-suppressor mechanisms can affect primary tumor devel-
opment without any significant impact on tumor metastatic
growth and vice versa. This dichotomy indicates that mecha-
nisms controlling primary tumor growth and metastasis could
be independent. We have shown here that, besides fostering
primary tumor development, T cell production of TGF-b1 facili-
tates tumor metastatic growth as indicated by the fact that
deletion of the Tgfb1 gene from T cells also inhibited the col-
onization of lungs by the aggressive B16 tumors as well as the
establishment of the peritoneal cavity by EL-4 tumors. These
findings uncovered surprisingly comprehensive effects of T cell
TGF-b1 production on tumor development and dissemination
and singularly revealed that absence of TGF-b1 from T cells is
sufficient to break tolerance to tumors.
Our findings showed enhancement of antitumor immune
responses in the absence of T cell-produced TGF-b1 indepen-
dent of tumor-produced TGF-b1. In contrast, work published
by several groups has shown that tumor-produced TGF-b
promotes tumor escape from immune surveillance (Frieseet al., 2004; Kao et al., 2003; Liu et al., 2007; Torre-Amione
et al., 1990). One explanation for these different findings is that
most of these studies based their conclusions on observations
of specific cell lines or transplanted tumors. It is plausible that
mechanisms of TGF-b-mediated T cell tolerance differ between
primary and transplanted models. The TGF-b receptors are
widely expressed in tumor cells and multiple lineages of tumor
stromal cells (Massague´, 2008). Tumor cells and other cells in
the immediate vicinity of the tumor will most probably consume
TGF-b secreted by tumors before it reaches the draining lymph
nodes to regulate T cell differentiation. Thus, tumor-derived
TGF-b1 probably makes only a minor contribution to the
observed TGF-b-mediated T cell tolerance, which we demon-
strated is initiated at the stage of T cell priming. Nevertheless,
the definitive function of tumor cell-produced TGF-b1 in control
of tumor immunosurveillance awaits the generation of tumor
cell-specific TGF-b1-deficient mice.
In conclusion, we have revealed in this report a TGF-b1-
dependent mechanism that subverts T cell antitumor responses
resulting in ineffective control of tumor growth and metastasis.
These findings may have profound implications for targeting
TGF-b for cancer immunotherapy. A systemic TGF-b blocking
strategy will probably neutralize all the TGF-b, and hosts lose
the benefits of the cytostatic effects of TGF-b on tumor cells
(Pu et al., 2009). Targeted blockade of the self-directed TGF-b
signaling pathway in T cells will probably provide a better
strategy to specifically awaken antitumor immunity and eradi-
cate cancer.EXPERIMENTAL PROCEDURES
Mice
TRAMP, DNR, and HRC TCR transgenic mice and mice with floxed and null
alleles of Tgfb1 gene have previously been described (Gorelik and Flavell,
2000; Greenberg et al., 1995; Li et al., 2007; Savage et al., 2008). Wild-type
TRAMP mice were crossed with DNR mice or mice with null alleles of Rag-1
gene to generate DNR-TRAMP or Rag1/-TRAMP mice, respectively.
Crossing mice with floxed and null alleles of Tgfb1 gene (f/n) with CD4-Cre
or Foxp3-Cre mice generated Tgfb1f/n Cd4cre (TKO) or Tgfb1f/n Foxp3cre
(TregKO) mice. TKO-TRAMP or TregKO-TRAMP mice were produced by
crossing Tgfb1f/n Cd4cre or Tgfb1f/n Foxp3cre mice to wild-type TRAMP
mice. All mice were maintained under specific-pathogen-free conditions,
and animal experimentation was conducted in accordance with institutional
guidelines.Tumor Cell Lines and Injections
Ovalbumin-expressing B16 melanoma cells and EL-4 cells were cultured
in vitro in DMEM and RPMI-1640 media, respectively, supplemented with
10% fetal calf serum, 0.1 mM glutamine, and 10 U/ml penicillin. B16 mela-
noma tumor cells were collected by incubation in 0.25% trypsin. Tumor cells
were washed twice in endotoxin-free PBS and 1.0 3 105 or 1.0 3 106 cells in-
jected via tail vein (B16) or intraperitoneally (EL-4), respectively, in a volume of
0.2 ml PBS. Cell viability was at least 90% as determined by trypan blue
exclusion.Isolation of Tumor-Infiltrating Lymphocytes
Tumor tissues from sacrificed mice were prepared by mechanical disruption
followed by 1 hr treatment with 0.5 mg/ml collagenase Type D at 37C in
a shaker. Digested tissues were mashed between glass slides, layered on
a percoll gradient, and centrifuged at 3000 rpm for 30 min. The separated
tumor-infiltrating lymphocyte (TIL) fraction was washed twice in PBS
before use.Immunity 35, 123–134, July 22, 2011 ª2011 Elsevier Inc. 131
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Fluorescently labeled antibodies against B220, CD4, CD8, TCR-b, CD45,
GzmB, Foxp3, PD-1, and IFN-g markers were purchased from eBio-
sciences. Fluorescently labeled anti-goat IgG was obtained from Jackson Im-
munoresearch. Phospho-Smad2/3 (Ser 423/425, clone sc-11769) antibody
was obtained from Santa Cruz Biotechnology. Splenocytes and lymph node
cells were depleted of erythrocytes by hypotonic lysis. Splenocytes, lymph
node cells, and TILs were incubated with specific antibodies for 20 min on
ice in the presence of 2.4G2 mAb to block FcgR binding. p-Smad2/3, IFN-g,
and GzmB staining were carried out with the nuclear protein or the intracellular
cytokine staining kits from eBiosciences and BD Biosciences. For intracellular
cytokine staining, cells were stimulated with 50 ng/ml phorbol 12-myristate
13-acetate (PMA, Sigma), 1 mM ionomycin (Sigma), and GolgiStop (BD Biosci-
ences) for 4–5 hr. After stimulation, cells were stained with cell surface marker
antibodies, fixed, and permeabilized with a Cytofix/Cytoperm kit (BD Biosci-
ences). All samples were acquired with LSR II flow cytometer (Becton Dickin-
son) and analyzed with FlowJo software (Tree Star).
Enzyme-Linked Immunosorbent Assay
A mixture of MicroBeads (Miltenyi Biotec)-purified lymph node CD4+ and
CD8+ T cells from 8-month-old tumor-bearing TRAMP mice was cultured
in serum-free Nutridoma medium (Roche). After 24 hr, TGF-b1 concentra-
tions in cell supernatants, normalized to the number of live cells, were deter-
mined. Latent TGF-b1 in the culture supernatant was activated by acid treat-
ment and assayed with antibody pairs from R&D Systems (BAF240 and
MAB1835).
T Cell Transfer
Congenically marked HRC (CD45.1/CD45.1) and DNR-HRC (CD45.1/CD45.2)
CD8+ T cells were purified from TCR transgenic mice that had been crossed to
Rag1-deficient background with MicroBeads (Miltenyi Biotec). HRC and
DNR-HRC CD8+ T cells were mixed at a ratio of 1:1 and labeled with CFSE.
A total of 2 3 105 cells were injected via tail vein into 8-month-old tumor-
bearing CD45.2/CD45.2 TRAMP mice. Recipient mice were analyzed
12 days after the transfer.
Histopathology, Immunohistochemistry, and Pulmonary Nodule
Enumeration
Dissected prostates and lungs from sacrificed animals were fixed in 10% buff-
ered neutral formalin and embedded in paraffin. For macroscopic pulmonary
nodule analysis, lungs were fixed in Bouin’s fixative and the number of metas-
tases counted with a dissecting microscope. For histopathological and imuno-
histochemical analyses, 4–5 mm tissue sections were routinely stained with
hematoxylin and eosin and microscopically examined for the stages of tumor
development. For immunohistochemical analyses, tissues sections were
stained with CD3 antibody. Tumor stage classification followed the criteria
as previously described (Hurwitz et al., 2001).
Antitumor Cytolytic Assay
Freshly isolated splenocytes were depleted of erythrocytes by hypotonic lysis
and evaluated for their anti-EL-4 lytic activity as described (Gorelik and Flavell,
2001). Chromium-51-labeled target EL-4 cells were incubated with effector
splenocytes at different effector:target ratios for 4 hr. The release of radioac-
tive Cr was measured with a g-counter (Perkin Elmer) and the percentage of
specific Cr-51 release was calculated by the formula: [(CPMexperimental 
CPMspontaneous)/(CPMmaximum CPMspontaneous)]3 100; where CPMexperimental
is Cr-51 release by target cells incubated with effector cells, CPMspontaneous is
Cr-51 release by equivalent number of targets without effector cells, and
CPMmaximum is total Cr-51 release after addition of 2% Triton X-100 to an
equivalent number of target cells.
Statistical Analysis
Student’s t test was used to calculate statistical significance for difference
in a particular measurement between groups. The Wilcoxon rank-sum test
was used to assess differences between samples that did not meet the
assumptions of normality. A p value of <0.05 was considered statistically
significant.132 Immunity 35, 123–134, July 22, 2011 ª2011 Elsevier Inc.SUPPLEMENTAL INFORMATION
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